Maxim Sorokin

Mr. Maxim Sorokin

Russian Cancer Research Center NN Blokhin, Moscow, Moskva, Russia
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 June 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
OKOlga Kovaleva
Olga Kovaleva
Polina PodlesnayaPolina Podlesnaya
Polina Podlesnaya
MSMaxim Sorokin
Maxim Sorokin
VMValeria Mochalnikova
Valeria Mochalnikova
Vladimir KataevVladimir Kataev
Vladimir Kataev
Alexei GratchevAlexei Gratchev
Alexei Gratchev
The identification of new prognostic markers of renal cell carcinoma (RCC) is an urgent problem in oncourology. To investigate the potential prognostic significance of tumor microbiome and stromal inflammatory markers, we studied a cohort of 66 patients with RCC (23 clear cell RCC, 19 papillary RCC and 24 chromophobe RCC). The microbiome was analyzed in tumor and normal tissue by 16S rRNA amplicon sequencing. Characterization of the tumor stroma was performed using immunohistochemistry. A significant difference in alpha diversity was demonstrated between normal kidney tissue and all types of RCC. Further, we demonstrated that the bacterial burden was higher in adjacent normal tissue than in a tumor. For the first time, we demonstrated a significant correlation between bacterial burden and the content of PU.1+ macrophages and CD66b+ neutrophils in kidney tumors. Tumors with high content of PU.1+ cells and CD66b+ cells in the stroma were characterized by a lower bacterial burden. In the tumors with high bacterial burden, the number of PU.1+ cells and CD66b+ was associated with a poor prognosis. The identified associations indicate the great prognostic potential of a combined tumor microbiome and stromal cell analysis.